![Alvin Shih](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alvin Shih
Direktor/Vorstandsmitglied bei
ZEVRA THERAPEUTICS, INC.
Vermögen: 234 800 $ am 31.08.2026
Profil
Alvin Shih is President, Chief Executive Officer & Director at Catamaran Bio, Inc. since 2021.
Dr. Shih is Chief Executive Officer & Director at Imbria Pharmaceuticals, Inc. starting 2025.
Dr. Shih is Independent Director at Oaktree Acquisition Corp.
III Life Sciences since 2024.
Dr. Shih is Independent Director at Zevra Therapeutics, Inc. since 2024.
Dr. Shih is Director at Rare-X.
Former roles include Chief Executive Officer at Disarm Therapeutics, Inc. from 2019 to 2020, Chief Executive Officer at Enzyvant Therapeutics, Inc. from 2016 to 2019, Executive Vice President-Research & Development at Travere Therapeutics, Inc. from 2015 to 2016, and Chief Operating Officer at Pfizer Inc. from 2010 to 2014.
Education includes undergraduate degree from Vanderbilt University, MBA from Kellogg School of Management, and doctorate from The University of Alabama School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2026 | 20’000 ( 0.03% ) | 234 800 $ | 31.08.2026 |
Aktive Positionen von Alvin Shih
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 20.01.2024 |
Rare-X
 Rare-X Packaged SoftwareTechnology Services Operates as a patient data processing platform | Direktor/Vorstandsmitglied | - |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Vorstandsvorsitzender | 10.04.2025 |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Vorstandsvorsitzender | 01.02.2021 |
Ehemalige bekannte Positionen von Alvin Shih
| Unternehmen | Position | Ende |
|---|---|---|
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat patients with neurological diseases | Vorstandsvorsitzender | 01.12.2020 |
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Vorstandsvorsitzender | 01.02.2019 |
| TRAVERE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.10.2016 |
| PFIZER INC. | Geschäftsführer | 01.05.2014 |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Vorstandsvorsitzender | - |
Ausbildung von Alvin Shih
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
72
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Zevra Therapeutics, Inc.
 Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Travere Therapeutics, Inc.
 Travere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in developing and delivering life-changing therapies to people living with rare kidney, liver & metabolic diseases | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Alabama School of Medicine
 The University of Alabama School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat patients with neurological diseases | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Health Technology |
Enzyvant Therapeutics, Inc.
Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Health Technology |
Rare-X
Rare-X Packaged SoftwareTechnology Services Operates as a patient data processing platform | Technology Services |
